13F reference period
Q2 2026
Security Snapshot
Arcadia Biosciences, Inc. - Common (RKDA) Institutional Ownership
CUSIP: 039014303
13F Institutional Holders and Ownership History from Q1 2023 to Q3 2026
Institutions Reporting
16
Shares (Excl. Options)
211.49K
Full value: 211,485 · shares · 30 Jun 2026Price
$0.68
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common
- Symbol
- RKDA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 211,485
- Total 13F value
- $145,768
- Portfolio coverage rank
- 0%
- Share change
- -137,895
- Value change
- -$298,191
- Number of holders
- 16
- Shares outstanding
- 2,412,357
- SEC-reported price per share
- $0.21
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- RKDA - Arcadia Biosciences, Inc. - Common is tracked under CUSIP 039014303.
- 16 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 15 to 16 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$482.14K
Full value: $482,143 · USD · 31 Mar 2026.$145.77K
Full value: $145,768 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 16 institutions filings for Q2 2026.
Security key
039014303
13F reference period
Q2 2026
13F holders
16
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
RKDA full holder history
Arcadia Biosciences, Inc. SEC filings
Arcadia Biosciences, Inc. company facts
Arcadia Biosciences, Inc. insider transactions
Arcadia Biosciences, Inc. 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 039014303:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
RKDA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MJL Manager LLC | 16% | $178,008 | 378,740 | MJL Manager LLC | 25 Sep 2026 | |||
| ARMISTICE CAPITAL, LLC | 10% | $181,586 | 267,392 | Armistice Capital, LLC | 30 Jun 2026 |
As of 30 Jun 2026,
16
institutional investors reported holding
shares of
Arcadia Biosciences, Inc. - Common (RKDA).
This represents
8.8%
of the company’s total
outstanding shares.
211.49K
Full value: 211,485 · shares · 30 Jun 20262.41M
Full value: 2,412,357 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
15
Headline period
Q2 2026
Rows shown
1-15 of 15
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 192 | $54 | $0.28 | 3 | |
| 2026 Q2 | 211,485 | $145,768 | -$298,191 | $0.68 | 16 |
| 2026 Q1 | 349,380 | $482,143 | +$428,111 | $1.38 | 15 |
| 2025 Q4 | 39,114 | $77,444 | -$85,431 | $1.98 | 13 |
| 2025 Q3 | 65,469 | $227,175 | +$21,427 | $3.47 | 16 |
| 2025 Q2 | 59,229 | $259,133 | -$74,370 | $4.31 | 14 |
| 2025 Q1 | 76,493 | $222,115 | -$6,350 | $2.97 | 14 |
| 2024 Q4 | 78,535 | $464,928 | +$150,707 | $5.92 | 13 |
| 2024 Q3 | 53,913 | $149,017 | +$68,828 | $2.75 | 13 |
| 2024 Q2 | 28,701 | $90,408 | -$116,787 | $3.15 | 10 |
| 2024 Q1 | 80,957 | $178,327 | -$136,659 | $2.20 | 12 |
| 2023 Q4 | 138,529 | $430,741 | +$283,457 | $3.13 | 13 |
| 2023 Q3 | 47,444 | $158,572 | -$308,268 | $3.34 | 10 |
| 2023 Q2 | 138,672 | $538,046 | -$422,672 | $3.88 | 11 |
| 2023 Q1 | 161,885 | $1,209,095 | +$1,209,095 | $7.47 | 13 |